Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

QR Code

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine involving the use of the same or similar radiopharmaceutical agents for the diagnosis and treatment of patients. Prostate-specific membrane antigen (PSMA) is a promising theranostic target for the treatment o...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kristin A. Plichta, Stephen A. Graves, John M. Buatti
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	theranostics PSMA oligometastatic prostate cancer Biology (General) QH301-705.5 Chemistry QD1-999
Accès en ligne:	https://doaj.org/article/e9d9fc024dc8467ab1dd9078ae9a8eb3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
par: Cihan Gündoğan, et autres
Publié: (2021)

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
par: William John Yaxley, et autres
Publié: (2021)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
par: Maximilian A. Kirchner, et autres
Publié: (2021)

Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study
par: Jarosław B. Ćwikła, et autres
Publié: (2021)

Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer
par: Julien Van Damme, et autres
Publié: (2021)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
par: Bastiaan M. Privé, et autres
Publié: (2021)

Design and synthesis of a new conjugate of a tris(3-hydroxy-4-pyridinone) chelator (KC18) for potential use as gallium-68-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical
par: Xu Zhou, et autres
Publié: (2021)

Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease
par: Yilin Cao, et autres
Publié: (2021)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
par: Hanane Lahnif, et autres
Publié: (2021)

68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors
par: Heying Duan, et autres
Publié: (2022)

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
par: Paola Mapelli, et autres
Publié: (2021)

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice
par: Xia L, et autres
Publié: (2021)

Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI
par: Wei Liu, et autres
Publié: (2022)

Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
par: Sabine Wächter, et autres
Publié: (2021)

[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
par: Martina Sollini, et autres
Publié: (2021)

Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
par: Sillerud LO
Publié: (2016)

SABR in oligometastatic breast cancer: Current status and future directions
par: Rachel Stewart, et autres
Publié: (2021)

Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report
par: Anne-Emmanuella Yeo, et autres
Publié: (2021)

Oligometastatic non-small-cell lung cancer: current treatment strategies
par: Richard PJ, et autres
Publié: (2016)

Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
par: Nnabugwu II, et autres
Publié: (2014)

Prostate-Specific Antigen and Testosterone Levels as Biochemical Indicators of Cognitive Function in Prostate Cancer Survivors and the Role of Diabetes
par: Alicja Popiołek, et autres
Publié: (2021)

Prostate cancer and prostatic diseases
Publié: (1997)

Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity
par: Ondrej Vit, et autres
Publié: (2021)

Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria
par: Nnabugwu II, et autres
Publié: (2016)

Prospective investigation of change in the prostate-specific antigens after various urologic procedures
par: Park SC, et autres
Publié: (2015)

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer
par: Danyang Zhou, et autres
Publié: (2021)

Highly portable quantitative screening test for prostate-specific antigen at point of care
par: Balaji Srinivasan, et autres
Publié: (2021)

Correlation of prostate volume with 'International Prostate Symptom Score' and 'Benign Prostatic Hyperplasia-Impact Index' in benign prostatic hyperplasia
par: D Gnyawali, et autres
Publié: (2016)

The prostate journal
Publié: (1999)

Prostate cancer
Publié: (2011)

Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
par: Xing Zhou, et autres
Publié: (2022)

A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
par: Srikanth Boinapally, et autres
Publié: (2021)

Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer
par: Michael Chaloupka, et autres
Publié: (2021)

Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
par: David L. Billing, et autres
Publié: (2021)

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
par: Mathieu Gauthé, et autres
Publié: (2021)

Chronic prostatitis alters the prostatic microenvironment and accelerates preneoplastic lesions in C57BL/6 mice
par: Gao,Yong, et autres
Publié: (2019)

Gold nanoparticle-based colorimetric method for the detection of prostate-specific antigen
par: Xia N, et autres
Publié: (2018)

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL
par: Chen N, et autres
Publié: (2017)

Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
par: Yu Li, et autres
Publié: (2021)

Spectrum of conditionally pathogenic microflora isolated from the prostate secret in chronic bacterial prostatitis patients
par: T. V. Tunik, et autres
Publié: (2017)